1. Home
  2. SCYX vs WVVI Comparison

SCYX vs WVVI Comparison

Compare SCYX & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • WVVI
  • Stock Information
  • Founded
  • SCYX 1999
  • WVVI 1983
  • Country
  • SCYX United States
  • WVVI United States
  • Employees
  • SCYX N/A
  • WVVI N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • WVVI Beverages (Production/Distribution)
  • Sector
  • SCYX Health Care
  • WVVI Consumer Staples
  • Exchange
  • SCYX Nasdaq
  • WVVI Nasdaq
  • Market Cap
  • SCYX 28.5M
  • WVVI 28.2M
  • IPO Year
  • SCYX 2014
  • WVVI N/A
  • Fundamental
  • Price
  • SCYX $0.72
  • WVVI $4.76
  • Analyst Decision
  • SCYX
  • WVVI
  • Analyst Count
  • SCYX 0
  • WVVI 0
  • Target Price
  • SCYX N/A
  • WVVI N/A
  • AVG Volume (30 Days)
  • SCYX 200.7K
  • WVVI 26.9K
  • Earning Date
  • SCYX 08-07-2025
  • WVVI 08-12-2025
  • Dividend Yield
  • SCYX N/A
  • WVVI N/A
  • EPS Growth
  • SCYX N/A
  • WVVI N/A
  • EPS
  • SCYX N/A
  • WVVI N/A
  • Revenue
  • SCYX $2,630,000.00
  • WVVI $38,520,945.00
  • Revenue This Year
  • SCYX $410.22
  • WVVI N/A
  • Revenue Next Year
  • SCYX $248.83
  • WVVI N/A
  • P/E Ratio
  • SCYX N/A
  • WVVI N/A
  • Revenue Growth
  • SCYX N/A
  • WVVI N/A
  • 52 Week Low
  • SCYX $0.66
  • WVVI $3.17
  • 52 Week High
  • SCYX $2.28
  • WVVI $7.18
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 46.77
  • WVVI 28.99
  • Support Level
  • SCYX $0.67
  • WVVI $4.69
  • Resistance Level
  • SCYX $0.83
  • WVVI $5.75
  • Average True Range (ATR)
  • SCYX 0.05
  • WVVI 0.28
  • MACD
  • SCYX 0.01
  • WVVI -0.06
  • Stochastic Oscillator
  • SCYX 46.35
  • WVVI 5.63

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About WVVI Willamette Valley Vineyards Inc.

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

Share on Social Networks: